Health
Affinity’s COVID-19 antibodies ready for clinical trials – BSA bureau
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
Melbourne-based Affinity Biosciences Pty Ltd (Affinity) has lodged a pre-publication submission to the scientific journal, ‘mAbs’, detailing its results and observations relating to the discovery of potent antibodies against COVID-19.
This can be found at the link,’Anti…
-
Business24 hours agoHow your ASX shares may be impacted by US tariffs
-
Business21 hours agoWhy Amotiv, Breville, Life360, and Woodside shares are tumbling today
-
Noosa News22 hours agoWith The Horrors, Clown Core, a Car Crash and an Artist Inside an Hourglass on Its 2025 Lineup, Dark Mofo Is Definitely Back
-
Noosa News24 hours agoUte of missing woman found months after mysterious disappearance